Meet the leadership team that's helping transform surgery, advance care, and change lives.
Meet the leadership team that's helping transform surgery, advance care, and change lives.
Chief Executive Officer
Chris Barry serves as our chief executive officer and a member of the NuVasive Board of Directors.
Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations at Medtronic, its second largest business unit with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.
Vice President, Information Technology
Aviva McPherron serves as our vice president, information technology, and is responsible for the Company’s information technology organization. Ms. McPherron’s previous roles include vice president of enterprise applications and senior director of business solutions.
Before joining NuVasive, she was director of operations for Tapestry Solutions, a Boeing Company, and has held multiple technical leadership positions delivering transformative solutions. Ms. McPherron holds a bachelor’s degree in mechanical engineering from Stanford University.
Senior Vice President, Global Operations
Dale Wolf serves as senior vice president, global operations, and is responsible for supply chain & field logistics, distribution, manufacturing, quality assurance, international operations, real estate & facilities and the business transformation office. Mr. Wolf was most recently vice president of manufacturing for NuVasive, where he led our West Carrollton, Ohio, facility and the growth and development of manufacturing strategy.
Prior to joining NuVasive, Mr. Wolf spent more than 15 years at General Electric (GE), and has extensive experience in medical device manufacturing operations. He held various leadership roles managing GE Healthcare manufacturing facilities, streamlining new product introductions, and implementing Lean Six Sigma and continuous improvement platforms. Mr. Wolf holds a bachelor’s degree in mechanical engineering from the University of Wisconsin-Madison, and a Six Sigma Green Belt certification.
Vice President, Clinical, Medical, and Regulatory Affairs
Kyle Malone serves as our vice president of clinical, medical, and regulatory affairs and is responsible for NuVasive’s global regulatory and clinical strategies. Over the past decade, Mr. Malone has held positions of increasing leadership within NuVasive’s clinical teams and has served in various cross-functional management capacities.
Before joining NuVasive, he served as the director of research for the NNI Research Foundation in Las Vegas, Nevada. Mr. Malone holds dual master’s degrees from Tulane University and The Johns Hopkins University in neuroscience and music / pedagogy, respectively.
Chief Commercial Officer
Massimo Calafiore serves as our chief commercial officer and is responsible for the Company’s product marketing, commercial, and commercial enablement functions, as well as NuVasive Specialized Orthopedics and NuVasive Clinical Services.
Since joining the Company in 2017, Mr. Calafiore has held various leadership roles with increasing levels of responsibility, most recently serving as executive vice president, Global Business Units. Before NuVasive, he spent more than 15 years supporting and leading the U.S. business for Waldemar Link, a leader in the orthopedics and medical device industry. Mr. Calafiore holds a bachelor’s degree in mechanical engineering from the Università di Catania and a master of business administration degree from New York University.
Executive Vice President and Chief Financial Officer
Matt Harbaugh serves as our executive vice president and chief financial officer, and is responsible for all financial aspects of the Company, including accounting, financial planning and analysis, tax and treasury.
Prior to this role, Mr. Harbaugh worked at Mallinckrodt for nearly 10 years, most recently serving as the president of the specialty generics business, and spent more than five years as Mallinckrodt’s chief financial officer. Prior to this, he spent 10 years at Covidien in various finance leadership roles, and, most notably, helped lead the spin-off of Covidien Pharmaceuticals as Mallinckrodt Pharmaceuticals in July 2013. In addition, Mr. Harbaugh served in various finance leadership roles at Monsanto Company within its international regions. He received a bachelor’s degree in business administration from Saint Louis University and an executive master of business administration degree from Kellogg School of Management at Northwestern University.
Vice President, Corporate Marketing, Brand and Communication
Michael Farrington serves as our vice president, corporate marketing, brand and communication, and is responsible for the Company’s marketing strategy, brand, marketing technology, global events, public relations and communication functions.
Before joining NuVasive, he held a variety of corporate, brand and product marketing positions in global, medical technology companies including Becton Dickinson, CareFusion and Cardinal Health. Mr. Farrington holds a bachelor’s degree in business administration from Pepperdine University.
Senior Vice President, General Counsel and Corporate Secretary
Nathaniel Sisitsky, Esq., serves as our senior vice president, general counsel and corporate secretary, and is responsible for NuVasive’s legal functions, global risk and integrity and the NuVasive Spine Foundation.
Previously, Mr. Sisitsky served as NuVasive’s vice president and associate general counsel. Before joining NuVasive, he held a variety of legal positions, including vice president and associate general counsel, corporate governance and securities and M&A at CareFusion; and vice president, legal – corporate finance, at American Tower Corporation. Prior to joining American Tower, Mr. Sisitsky was a junior partner in the corporate department of Wilmer Cutler Pickering Hale and Dorr (WilmerHale). Mr. Sisitsky holds a bachelor’s degree in political science and economics from Emory University, and a Juris Doctor degree from New York University School of Law.
Chief Technology Officer
Ryan Donahoe serves as our chief technology officer and is responsible for spine research and development (R&D).
Since 2006, Mr. Donahoe has held various R&D leadership roles at NuVasive, and most recently served as vice president, Spine R&D. As one of the Company’s longest tenured employees, Mr. Donahoe has played an integral role in shaping the Company’s comprehensive, procedurally integrated spine portfolio and has more than 20 issued and pending patents. Prior to his career at NuVasive, he held engineering roles at both Zimmer Biomet and General Dynamics Land Systems. Mr. Donahoe has a bachelor’s degree in mechanical engineering from the University of California, Santa Barbara and a master’s degree in mechanical engineering from the University of California, San Diego.
Senior Vice President, Strategy and Corporate Development
Sean Freeman serves as our senior vice president, strategy and corporate development. In this capacity, he oversees global corporate and geographic strategy, leads inorganic and venture initiatives, and manages the integration function.
Prior to joining NuVasive, Mr. Freeman held the same role at the Cole-Parmer Instrument Company and led corporate development at Life Technologies, a global life sciences tools company acquired by Thermo Fisher Scientific in 2015. Prior to Life Technologies, he was an investment banker in the M&A group at Merrill Lynch & Co. in New York. Mr. Freeman is a CFA charterholder, holds a bachelor’s degree in commerce from the University of the Witwatersrand, and earned a master of business administration degree from The Wharton School at the University of Pennsylvania.
Amy Belt Raimundo has served as a member of our board of directors since August 2021. Ms. Raimundo has more than 20 years of experience in healthcare and is currently the co-founder and Managing Partner for Convey Capital, a venture capital fund focused on making investments in healthcare technology. She has more than 10 years of venture capital experience and has worked with various funds, such as Kaiser Permanente Ventures, Covidien Ventures, and Advanced Technology Ventures, investing in companies and technologies to help transform the future of healthcare. Ms. Raimundo also has extensive business operations experience, having served as Chief Business Officer at Evidation Health, in operating roles at Guidant Corporation, and as a management consultant for APM/CSC Healthcare. Ms. Raimundo is a co-founder of MedtechWomen, a nonprofit organization dedicated to highlighting women leaders in the medical technology industry. She earned a bachelor’s degree in economics from Yale University and a master of business administration degree from the University of California, Berkeley.
Chris Barry serves as our chief executive officer and a member of the NuVasive board of directors.
Prior to joining NuVasive, Mr. Barry served as senior vice president and president of surgical innovations at Medtronic, its second largest business unit with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Mr. Barry provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, advanced surgical technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.
Daniel J. Wolterman has served as a member of our board of directors since July 2015 and as board chair since May 2021. Mr. Wolterman is currently chief executive officer of Wolterman Consulting, a provider of strategic and operational consulting services to healthcare providers and other entities. From January 2018 to May 2019, Mr. Wolterman served as chief executive officer of ColubrisMX and X-Cath, both privately held medical device companies. Mr. Wolterman previously served as president and chief executive officer of Memorial Hermann Health System, the largest not-for-profit health system in Southeast Texas, from 2002 until his retirement from Memorial Hermann in May 2016. He has more than 38 years of experience in the healthcare industry and a long history of community involvement. He currently serves as a member of the board of directors of Vizient. Mr. Wolterman earned a bachelor’s degree in business administration and a master of business administration degree in finance from the University of Cincinnati, and a master’s degree in healthcare administration from Xavier University.
Donald J. Rosenberg has served as a member of our board of directors since February 2016. Mr. Rosenberg is currently the executive vice president, general counsel and corporate secretary of QUALCOMM Incorporated, a global leader in the development and commercialization of wireless technologies. Prior to joining QUALCOMM in October 2007, he served as senior vice president, general counsel and corporate secretary of Apple. Prior to that, Mr. Rosenberg held numerous positions at IBM Corporation, including senior vice president and general counsel. Mr. Rosenberg is a member of the Council on Foreign Relations, the International Advisory Board, University of California San Diego (UCSD) School of Global Policy and Strategy, and the China Leadership Board for the 21st Century China Center at UCSD. He has served as an adjunct professor of law at New York’s Pace University School of Law, where he taught courses in intellectual property and antitrust law. He received a bachelor’s degree in mathematics from the State University of New York at Stony Brook and a Juris Doctor degree from St. John’s University School of Law.
John DeFord, Ph.D. has served as a member of our board of directors since February 2018. Dr. DeFord previously served as the executive vice president and chief technology officer for Becton, Dickinson and Company (BD), a global medical technology company, until his retirement in May 2021. While at BD, Dr. DeFord also served as the senior vice president, research and development for the interventional segment from December 2017 to June 2018, following its acquisition of C.R. Bard where he had served as senior vice president, science, technology and clinical affairs since June 2007. Dr. DeFord joined Bard in 2004 and served in science and technology roles of increasing responsibility during that time. Prior to joining Bard, Dr. DeFord was managing director of Early Stage Partners, a venture capital fund. Prior to joining Early Stage Partners, Dr. DeFord was president and chief executive officer of Cook Incorporated, a privately held medical device manufacturer. He also serves on the board of directors of Nordson Corporation. Dr. DeFord graduated from Purdue University with a bachelor’s degree and master’s degree in electrical engineering and a Ph.D. in electrical/biomedical engineering.
Leslie V. Norwalk, Esq. has served as a member of our board of directors since May 2014. Ms. Norwalk is currently strategic counsel to Epstein Becker & Green, EBG Advisors and National Health Advisors. She also serves as a healthcare, regulatory and policy advisor to several private equity firms. Ms. Norwalk previously served the Bush Administration as the acting administrator for the Centers for Medicare & Medicaid Services. She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of Health Care Facilities and other federal health care initiatives. For four years prior to that, she was the agency’s deputy administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, she practiced law in the Washington, D.C. office of Epstein Becker & Green where she advised clients on a variety of health policy matters. She also served in the first Bush Administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative. Ms. Norwalk serves as a director of Arvinas, Magellan Health, Neurocrine Biosciences and ModivCare, as well as several privately held healthcare companies. She is also a member of APCO Worldwide’s International Advisory Council. Ms. Norwalk earned a bachelor’s degree, cum laude, in economics and international relations from Wellesley College and a Juris Doctor degree from the George Mason University School of Law.
Robert F. Friel has served as a member of our board of directors since February 2016. Mr. Friel most recently served as the chairman and chief executive officer of PerkinElmer, a global leader focused on improving the health and safety of people and the environment, until his retirement in December 2019. Mr. Friel served as PerkinElmer’s chief executive officer from February 2008 and chairman from April 2009 until December 2019. From August 2007 to January 2019, Mr. Friel also served as PerkinElmer’s president. Since joining PerkinElmer in February 1999 as chief financial officer, Mr. Friel also held the roles of chief operating officer and vice chairman and president of PerkinElmer’s life and analytical sciences unit. Prior to joining PerkinElmer, he held several senior management positions with AlliedSignal, now Honeywell International. Mr. Friel currently serves as a member of the board of directors of West Pharmaceutical Services and Xylem. Mr. Friel received a bachelor’s degree in economics from Lafayette College and a master’s degree in taxation from Fairleigh Dickinson University.
R. Scott Huennekens has served as a member of our board of directors since October 2018. Mr. Huennekens most recently served as the president, chief executive officer and chairman of the board for Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop surgical platforms including advanced surgical robotics, from August 2015 to December 2018. Prior to joining Verb Surgical, Mr. Huennekens was president, chief executive officer and a member of the board of directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens was president and chief executive officer at Digirad Corporation from 1997 to 2002, and previously served as its chief financial officer. Mr. Huennekens currently serves as the executive chairman of the board for Acutus Medical and as a member of the board of directors of Envista Holdings Corporation and ViewRay. Mr. Huennekens received a bachelor’s degree in business administration from the University of Southern California, and a master of business administration degree from Harvard Graduate School of Business.
Siddhartha Kadia, Ph.D., has served as a member of our board of directors since February 2021. Dr. Kadia most recently served as president and chief executive officer of EAG Laboratories, a global scientific services company providing analytical testing and consulting solutions, from 2014 to 2018. Prior to EAG Laboratories, Dr. Kadia spent nine years with Life Technologies and its predecessor Invitrogen Corporation. Dr. Kadia held various positions with increasing responsibilities, including marketing and operations roles, as well as leadership roles in Japan and China. Most notably, he served as President, Life Sciences Division at Life Technologies where he managed a $2 billion product portfolio. Prior to Life Technologies, Dr. Kadia was a management consultant at McKinsey & Company in the Healthcare Practice. Dr. Kadia currently serves as a member of the board of directors of ALS Limited. Dr. Kadia earned a bachelor’s degree in electronics and telecommunications from Gujarat University in India, a master’s degree in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University.
Vickie L. Capps has served as a member of our board of directors since June 2015. Ms. Capps is currently a senior advisory board member of Consonance Capital Partners, a healthcare investment firm. Ms. Capps previously served as chief financial officer of several public and private companies. From 2002 to 2013, Ms. Capps served as the executive vice president, chief financial officer and treasurer of DJO Global, a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management. Earlier in her career, she served as a senior audit and accounting professional at Ernst & Young. She also serves on the board of directors of Amedisys, Otonomy and Silverback Therapeutics. Ms. Capps is a California certified public accountant and was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. She earned a bachelor’s degree in business administration/accounting from San Diego State University.